In a major milestone for mental health care, Austin-based Choose Your Horizon Inc., also known as Choose Ketamine, has announced the completion of its seed financing round. Led by Manifestations Capital in collaboration with Notley Ventures and numerous industry veterans and thought leaders, this
Read More
The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it has been granted a Pre-Investigational New Drug (Pre-IND) meeting by the U.S. Food and Drug Administration (FDA) for new chemical entity Triptax™. Biomind Labs is devoted to crafting innovative pharmaceuticals for patients with neurological and psychiatric disorders, using
Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that
Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently
Psychedelic biopharmaceutical company Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announced today the dosing of the first two patients in the company’s Phase
One of the largest publicly listed ketamine focused clinic operations operating in the United States, Revitalist Lifestyle and Wellness Ltd. (CSE: CALM)
Psychedelic biotechnology company Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) announced today confirmation of regulatory approval from the U.K. Medicines and Healthcare
Biopharmaceutical company Short Wave Pharma Inc. has announced a signed Clinical Trial Agreement with the Sheba Fund for Health Services and Research. Dr. Eitan
Field Trip Health & Wellness Ltd. announced today that the company has filed the necessary listing application to list its common shares
Silo Pharma, Inc. (OTCQB: SILO), a development-stage psychedelic biopharmaceutical firm, announced that the company’s patented topically applied ketamine formulation has completed a
World-class psychedelic biotech firm Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that Former FDA Director Dr. Thomas Laughren has
Clinical‐stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) today announced the company’s participation in Project Solace, the
Evidence-based mental healthcare company Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC: KONEF) (FRA: SQ2) announced that its wholly-owned subsidiary KGK Science Inc. has entered into
Biopharmaceutical company Journey Colab who are working to unlock the science of psychedelics and build a new model for addiction treatment recently
